For patients without baseline CNS metastases, CIRs were higher for non-CNS progression than for CNS progression/death, suggesting that alectinib may prevent the spread of ALK-positive NSCLC to the brain, in addition to its activity against CNS metastases. Here, ALK is linked to non-small cell lung carcinoma.